English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Pimobendan is frequently used off‐label for treatments of cats with congestive heart failure (CHF). Concern exists regarding the safety of pimobendan in cats with outflow tract obstruction (OTO).    Objectives  In cats treated with pimobendan, incidence of adverse effects will not differ between cats with OTO vs cats with nonobstructive cardiomyopathy.    Animals  Two‐hundred sixty cats with CHF (57 with OTO, 203 with nonobstructive disease).    Methods  Retrospective medical record review. Groups were compared using 2‐sample  t ‐tests, Wilcoxon rank‐sum tests, and Fisher exact tests.    Results  Compared to cats with nonobstructive cardiomyopathy, cats with OTO were younger (8.9 [interquartile range (IQR) 6.6] vs 10.8 [6.3] years,  P  = .0036), more likely to have a heart murmur (51/57 [90%] vs 76/203 [37.8%] cats,  P  < .0001), more likely to manifest CHF as pulmonary edema (53/57 [83%] vs 144/203 [70.9%] cats,  P  = .0004), and less likely to have pleural effusion (19/57 [33%] vs 122/203 [60.1%] cats,  P  = .0005). Adverse effects suspected to be related to pimobendan administration occurred in 12/260 cats (4.6%), including 11/203 cats (5.4%) with nonobstructive cardiomyopathy and 1/57 cat (2%) with OTO ( P  = .7). Pimobendan was discontinued due to adverse effects in 4/260 cats (1.5%), 3 with nonobstructive disease and 1 with OTO ( P  = 1.0). Acute adverse hemodynamic effects after pimobendan administration were not detected in any cats.    Conclusions and Clinical Importance  Pimobendan is well tolerated in cats with cardiomyopathy and CHF, regardless of the presence of OTO.

Retrospective evaluation of the safety and tolerability of pimobendan in cats with obstructive vs nonobstructive cardiomyopathy